Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRF6021 in Primary Hip or Knee Arthroplasty
NCT03981419Phase 2Completed
- Sponsor
- Alkahest, Inc.
- Start
- Jul 2019
- Primary completion
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in postoperative recovery comparing GRF6021 with Placebo (2 arms). Primary endpoint: Effect of GRF6021 on Immune Responses to Surgery as Determined by Cytometry by Time of Flight (CyTOF) at Day 3. Started Jul 2019; status: completed.
02
Drugs
GRF6021
03
Conditions
postoperative recovery
Beyond the preview
Go deeper on NCT03981419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03981419.